Healthcare provider profile · identity verified

Edward J. Matta, MD

Internal Medicine · NEW YORK, NY · NPI 1851354203

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	955	127
Famotidine	Famotidine	774	103
Amlodipine Besylate	Amlodipine Besylate	501	75
Tamsulosin Hcl	Tamsulosin Hcl	408	63
Eliquis	Apixaban	406	54
Gabapentin	Gabapentin	327	44
Metoprolol Succinate	Metoprolol Succinate	316	44
Losartan Potassium	Losartan Potassium	315	45
Metoprolol Tartrate	Metoprolol Tartrate	306	39
Mirtazapine	Mirtazapine	297	44
Levothyroxine Sodium	Levothyroxine Sodium	267	43
Nifedipine Er	Nifedipine	243	32
Lisinopril	Lisinopril	242	41
Metformin Hcl	Metformin Hcl	192	38
Clopidogrel	Clopidogrel Bisulfate	175	24
Finasteride	Finasteride	175	26
Pantoprazole Sodium	Pantoprazole Sodium	168	30
Jardiance	Empagliflozin	161	24
Rosuvastatin Calcium	Rosuvastatin Calcium	150	28
Omeprazole	Omeprazole	146	21
Escitalopram Oxalate	Escitalopram Oxalate	139	20
Furosemide	Furosemide	133	23
Memantine Hcl	Memantine Hcl	127	20
Potassium Chloride	Potassium Chloride	121	15
Januvia	Sitagliptin Phosphate	119	18
Donepezil Hcl	Donepezil Hcl	116	15
Carvedilol	Carvedilol	113	32
Sertraline Hcl	Sertraline Hcl	113	16
Levetiracetam	Levetiracetam	100	19
Allopurinol	Allopurinol	97	11
Hydralazine Hcl	Hydralazine Hcl	97	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	97	30
Duloxetine Hcl	Duloxetine Hcl	95	suppressed
Baclofen	Baclofen	89	13
Simvastatin	Simvastatin	88	12
Lactulose	Lactulose	82	23
Latanoprost	Latanoprost	80	30
Torsemide	Torsemide	77	16
Montelukast Sodium	Montelukast Sodium	75	12
Trulicity	Dulaglutide	74	15
Entresto	Sacubitril/Valsartan	66	13
Divalproex Sodium	Divalproex Sodium	64	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	64	14
Trazodone Hcl	Trazodone Hcl	59	12
Colchicine	Colchicine	58	suppressed
Midodrine Hcl	Midodrine Hcl	57	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	56	suppressed
Spironolactone	Spironolactone	52	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	50	19
Albuterol Sulfate	Albuterol Sulfate	48	11
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	48	17
Perphenazine	Perphenazine	48	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	48	suppressed
Warfarin Sodium	Warfarin Sodium	46	suppressed
Oxycodone Hcl	Oxycodone Hcl	45	14
Risperidone	Risperidone	45	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	44	suppressed
Benztropine Mesylate	Benztropine Mesylate	43	suppressed
Tradjenta	Linagliptin	43	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	42	16
Ciclopirox	Ciclopirox Olamine	42	18
Ezetimibe	Ezetimibe	42	suppressed
Pravastatin Sodium	Pravastatin Sodium	39	suppressed
Nystatin	Nystatin	38	suppressed
Topiramate	Topiramate	37	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	36	suppressed
Incruse Ellipta	Umeclidinium Bromide	36	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	suppressed
Methimazole	Methimazole	36	suppressed
Sodium Chloride	0.9 % Sodium Chloride	34	suppressed
Fluticasone Propionate	Fluticasone Propionate	33	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	32	13
Bicalutamide	Bicalutamide	31	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	30	suppressed
Amoxicillin	Amoxicillin	29	suppressed
Citalopram Hbr	Citalopram Hydrobromide	29	suppressed
Anastrozole	Anastrozole	28	suppressed
Clonidine Hcl	Clonidine Hcl	28	suppressed
Xarelto	Rivaroxaban	28	suppressed
Olanzapine	Olanzapine	26	suppressed
Valsartan	Valsartan	26	suppressed
Metformin Hcl Er	Metformin Hcl	25	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	25	suppressed
Amiodarone Hcl	Amiodarone Hcl	24	suppressed
Icosapent Ethyl	Icosapent Ethyl	24	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	23	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	23	12
Isosorbide Dinitrate	Isosorbide Dinitrate	23	suppressed
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	22	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	22	suppressed
Lamotrigine	Lamotrigine	21	suppressed
Ozempic	Semaglutide	21	suppressed
Ursodiol	Ursodiol	21	suppressed
Folic Acid	Folic Acid	20	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	20	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	12
Timolol Maleate	Timolol Maleate	20	suppressed
Dorzolamide Hcl	Dorzolamide Hcl	19	suppressed
Lorazepam	Lorazepam	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Fluticasone-Vilanterol	Fluticasone/Vilanterol	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	12
Lamivudine	Lamivudine	18	suppressed
Alendronate Sodium	Alendronate Sodium	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	12
Cinacalcet Hcl	Cinacalcet Hcl	17	suppressed
Bupropion Hcl	Bupropion Hcl	16	suppressed
Gemtesa	Vibegron	16	suppressed
Letrozole	Letrozole	16	suppressed
Prednisolone Acetate	Prednisolone Acetate	16	suppressed
Tivicay	Dolutegravir Sodium	16	suppressed
Vancomycin Hcl	Vancomycin Hcl	15	suppressed
Abacavir	Abacavir Sulfate	14	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Prednisone	Prednisone	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Insulin Aspart Flexpen	Insulin Aspart	13	suppressed
Lokelma	Sodium Zirconium Cyclosilicate	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Admelog Solostar	Insulin Lispro	12	suppressed
Dextrose In Water	Dextrose 5 % In Water	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Exemestane	Exemestane	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error